Abstract |
Remarkable advances have been made in recent years towards therapeutics for cognitive impairment in individuals with Down syndrome (DS) by using mouse models. In this review, we briefly describe the phenotypes of mouse models that represent outcome targets for drug testing, the behavioral tests used to assess impairments in cognition and the known mechanisms of action of several drugs that are being used in preclinical studies or are likely to be tested in clinical trials. Overlaps in the distribution of targets and in the pathways that are affected by these diverse drugs in the trisomic brain suggest new avenues for DS research and drug development.
|
Authors | Ishita Das, Roger H Reeves |
Journal | Disease models & mechanisms
(Dis Model Mech)
Vol. 4
Issue 5
Pg. 596-606
(Sep 2011)
ISSN: 1754-8411 [Electronic] England |
PMID | 21816951
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Topics |
- Animals
- Behavior, Animal
- Brain
(pathology, physiopathology)
- Clinical Trials as Topic
- Cognition Disorders
(complications, physiopathology)
- Disease Models, Animal
- Down Syndrome
(complications, drug therapy, physiopathology)
- Humans
- Mice
|